Author Archives: Jennifer Ringler

Rare Disease Day: Spotlight on Solidarity

By Jennifer Ringler | Published: February 28, 2012
Patients, policymakers and pharmaceutical companies are uniting around rare diseases on the rarest of calendar days, presaging a leap forward in health outcomes and business opportunities. Aligning humanistic objectives with business incentives is often the sine qua non of effective community activism. This year’s Rare Disease Day – hosted in the US by the National [...]
Posted in Events, FDA, Global, Patient Communication, Strategy, healthcare, leadership, patient education, social media | Tagged , , , , , , , | Leave a comment

A Dialogue on Patient Access Programs

By Jennifer Ringler | Published: February 16, 2012
As health reforms sweep in major changes to our nation’s healthcare system, patient assistance and access programs  (PAPs) are rapidly evolving to assess and meet new needs. As millions of uninsured Americans gain some form of insurance coverage, manufacturer-sponsored PAPs face unprecedented challenges as they rise up to evolve the PAP model to best address [...]
Posted in Events | Tagged , , , , | Leave a comment

Close to Home: Is Good Health Communicable?

By Jennifer Ringler | Published: January 18, 2012
The 2011 Edelman Health Barometer suggests that—in the same way that we spread colds, diseases, and other illnesses from person to person—good health and healthy behaviors can also be spread. Can pharma play a pivotal role in the good-health epidemic? Energy. An active lifestyle. Mental and emotional stability. Absence of disease. Nutrition. These are some of [...]
Posted in Technology, healthcare, social media | Tagged , , , | 1 Comment

Call for Ad Stars Submissions!

By Jennifer Ringler | Published: December 14, 2011
Call for Ad Stars Submissions! It’s that time again for the editors of Pharm Exec to narrow down its choices for our annual Ad Stars feature, recognizing the most clever, unique and effective campaigns in pharma advertising over the past year.
Posted in Strategy | Leave a comment

Putting the M Back in M&A

By Jennifer Ringler | Published: December 13, 2011
Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large. Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from relying [...]
Posted in Agency Insight, Biotech, Deals, FDA | Tagged , , , | Leave a comment